SRC and melanoma: These results contrast with those supporting the use of SRC inhibitors in resistance settings in line with the upregulation of members of the SRC‐family kinases (Girotti et al, 2013) and downstream SRC‐dependent effectors such as MCF2 and VAV1, two DBL family members identified through a genetic screen as candidate drug resistance in melanoma cells (Feddersen et al, 2019).